Researchers develop blood test for stress

Published Date: 08 Mar 2023

Researchers at Indiana University School of Medicine have developed a blood test for stress. This test assesses a person's risk of stress,...

Read Full News

Latest News

Adding CBT to Quetiapine Significantly Reduces Suicide Risk in Mood Disorders

Adding CBT to Quetiapine Significantly Reduces Suicide Risk in Mood Disorders

FDA Approves ProlivRx, First At-Home Neuromodulation Device for MDD

FDA Approves ProlivRx, First At-Home Neuromodulation Device for MDD

Parental Illness Perceptions Drive Poor QoL in Children with Food Allergies

Parental Illness Perceptions Drive Poor QoL in Children with Food Allergies

Exercise May Be as Effective as Therapy for Alleviating Depression Symptoms

Exercise May Be as Effective as Therapy for Alleviating Depression Symptoms

Low-Intensity Ultrasound Brain Stimulation Safely Reduces Depression Symptoms

Low-Intensity Ultrasound Brain Stimulation Safely Reduces Depression Symptoms

Q4 2025 Recap: Psychiatry News and Updates

Q4 2025 Recap: Psychiatry News and Updates

Todays Updates

FDA Updates Label for Reduced Osteoarthritis Risk With BEAR Implant Over ACL Reconstruction Victoria Johnson

FDA approves a label update for the BEAR implant, which was previously approved in 2020.

AI Scribes Reduce Physician Burnout Within 30 Days, With Lee Schwamm, MD Lee Schwamm, MD

Physicians experience significant challenges with increasing administrative burdens impacting patient care. Study shows AI scribes can help reduce burnout.

NeurologyLive® Friday 5 — January 23, 2026 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending January 23, 2026.

Evaluating Durable Dysphagia Outcomes in OPMD: Insights From Early BB-301 Clinical Data Marco Meglio

Jerel Banks, MD, PhD, chief executive officer of Benitec Biopharma, reviews early phase 1b/2a clinical signals, mechanism, and next steps for BB-301 in oculopharyngeal muscular dystrophy.

Phase 1/2a Findings Lend Support for BB-301 in Oculopharyngeal Muscular Dystrophy Marco Meglio

Benitec Biopharma reveals promising results for BB-301, a gene therapy showing significant improvements in swallowing function for OPMD patients.

NeurologyLive® Brain Games: January 25, 2025 Marco Meglio, Louie Pasculli

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on the ALS Treatment pathways!

GLP-1 Discontinuation Results in Significant Weight Regain, With Michael Weintraub, MD

GLP-1 Discontinuation Results in Significant Weight Regain, With Michael Weintraub, MD

Todays Updates

FDA Updates Label for Reduced Osteoarthritis Risk With BEAR Implant Over ACL Reconstruction Victoria Johnson

FDA approves a label update for the BEAR implant, which was previously approved in 2020.

AI Scribes Reduce Physician Burnout Within 30 Days, With Lee Schwamm, MD Lee Schwamm, MD

Physicians experience significant challenges with increasing administrative burdens impacting patient care. Study shows AI scribes can help reduce burnout.

NeurologyLive® Friday 5 — January 23, 2026 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending January 23, 2026.

Evaluating Durable Dysphagia Outcomes in OPMD: Insights From Early BB-301 Clinical Data Marco Meglio

Jerel Banks, MD, PhD, chief executive officer of Benitec Biopharma, reviews early phase 1b/2a clinical signals, mechanism, and next steps for BB-301 in oculopharyngeal muscular dystrophy.

Phase 1/2a Findings Lend Support for BB-301 in Oculopharyngeal Muscular Dystrophy Marco Meglio

Benitec Biopharma reveals promising results for BB-301, a gene therapy showing significant improvements in swallowing function for OPMD patients.

NeurologyLive® Brain Games: January 25, 2025 Marco Meglio, Louie Pasculli

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on the ALS Treatment pathways!

GLP-1 Discontinuation Results in Significant Weight Regain, With Michael Weintraub, MD

GLP-1 Discontinuation Results in Significant Weight Regain, With Michael Weintraub, MD

Latest News

Adding CBT to Quetiapine Significantly Reduces Suicide Risk in Mood Disorders

FDA Approves ProlivRx, First At-Home Neuromodulation Device for MDD

Parental Illness Perceptions Drive Poor QoL in Children with Food Allergies

Exercise May Be as Effective as Therapy for Alleviating Depression Symptoms

Low-Intensity Ultrasound Brain Stimulation Safely Reduces Depression Symptoms

Q4 2025 Recap: Psychiatry News and Updates

News All Time

FDA Clears BrainsWay’s TMS Device for Adolescents with MDD Aged 15 to 21 Years

FDA Clears BrainsWay’s TMS Device for Adolescents with MDD Aged 15 to 21 Years

Single Dose of MM120 (LSD) Shows Lasting Anxiety Reduction in GAD: Phase 2b Results Chelsie Derman

A phase 2b trial finds a single 100 μg dose of MM120 reduced GAD symptoms with benefits lasting 12 weeks, highlighting the promise of psychedelic therapy.

FDA Releases CRL Detailing Safety Concerns for MDMA-Assisted Therapy in PTSD Chelsie Derman

MDMA’s CRL, now available to the public, cites gaps in safety data, selection bias, and limited durability.

Prenatal Opioid Pain Medications Likely Not Linked to Autism or ADHD Risk Chelsie Derman

A study suggests associations between opioids during pregnancy and neurodevelopmental disorders are mainly due to confounding factors, not causal effects.

Atopic Eczema Linked to Suicidal Ideation in Global Study of 30,000 Adults Chelsie Derman

EADV 2025 findings show patients with atopic eczema face greater risks of depression, anxiety, sleep disorders, and stigmatization.

FDA Initiates Acetaminophen Label Change, Leucovorin Approval for Cerebral Folate Deficiency Abigail Brooks, MA

The Agency initiated an acetaminophen label change to reflect evidence of potential harms in pregnant women and an approval of leucovorin for CFD.

Daily Ammoxetine at 40, 60 mg Outperforms Placebo for MDD in Phase 2 Trial Chelsie Derman

A phase 2 trial demonstrated the effectiveness, safety, and tolerability of ammoxetine (40 and 60 mg) in patients with major depressive disorder.

APhA, Coalition of Autism Scientists Cite Insufficient Data to Support Acetaminophen, Autism Link Abigail Brooks, MA

Both organizations defend the use of Tylenol during pregnancy, citing “rigorous” and “reputable” research suggesting it does not cause autism in children.

5 Psychiatry Headlines You Missed in September 2025 Chelsie Derman

This month in review focuses on innovative therapies in psychiatry, including MM120 for anxiety and ammoxetine for depression, as well as providing safety insights.

Q3 2025 Recap: Psychiatry News and Updates Chelsie Derman

Explore the latest advancements in psychiatry, including FDA updates, emerging therapies, and promising clinical trial results for mental health treatments.

I Tried to End My Life 3 Times: Today, I Help Others Fight for Theirs Diana Guzman, LMHC

Therapist Diana Guzman, LMHC, writes about attempting suicide despite counseling patients battling with suicidal ideation.

Early Heart Rate Slowing Predicts Magnetic Brain Stimulation Response in MDD Chelsie Derman

Study finds heart rate deceleration within 45 seconds of iTBS may serve as a biomarker for improved depression outcomes, regardless of stimulation site.

FDA Approves Risperidone Extended-Release Injectable for Bipolar I Disorder Chelsie Derman

FDA approves UZEDY, a long-acting risperidone injection, for adults with bipolar I disorder.

Digital Therapeutic Reduces Negative Symptoms of Schizophrenia in Phase 3 Trial Chelsie Derman

A new digital therapeutic, CT-155, shows promise in reducing negative symptoms of schizophrenia.

Soft Drinks Linked to Depression Through Gut Microbiota Alterations Chelsie Derman

New research links soft drink consumption to depression, revealing gut microbiota changes as a potential mediator, particularly in women.

Esmethadone Shows Promise as Adjunctive Treatment for Antidepressant Tolerance Chelsie Derman

Post-hoc analysis of a phase 3 trial reveals significant improvements in patients with MDD experiencing tachyphylaxis.

Recommended News For You

Enthusiasm for Transplant-Free Strategies for Low-Risk Relapsed Hodgkin Lymphoma

Prostate cancer early detection system eliminates need for biopsy.

Colon cancer and exercise: Can physical activity reprogram genes?

In a recent study, Kencur ginger's anti-cancer properties were discovered.

Elder Abuse: Red Flags to Look Out For While Receiving Care.

Study reveals link between new-onset type 2 diabetes and some obesity-related cancers

The diamonds that could find cancer

Recommended Articles For You

The Dark Side of Melanoma: Uncovering the Risk Factors and Prevention Strategies 

Tumor Evolution: Signaling, Cancer Cell Plasticity, and Intratumor Heterogeneity 

Chemotherapy Advances: Albumin I.V., Trastuzumab, Liposomal Doxorubicin & More 

A New Hope: How Procarbazine is Revolutionizing Cancer Treatment 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

A researcher has found that yoga exhibits the "most improvement" in helping long-term cancer survivors restore their brain health.

2.

King Charles' Cancer; COVID Vax Now or Later; Was RFK Jr. a Drug Dealer?

3.

EGFR Inhibitors for Lung Cancer Tied to Increased Keratitis Risk.

4.

Drug-chemo combo increases cancer treatment efficacy

5.

New drug combination shows good results in patients with HPV-negative head and neck cancer

1.

Can We Repurpose BV-CHP for Better Outcomes in Peripheral T-Cell Lymphoma?

2.

Unlocking the Potential of Red Bone Marrow in the Formation of Blood Cells

3.

Unveiling the Mystery Behind Castleman Disease – Understanding Its Causes and Symptoms 

4.

Esophageal Cancer Survival Rates and Outcomes: Evidence-Based Insights from Oncology Studies

5.

Thyroid Cancer and Insulin Resistance: Unraveling the Complex Interplay for Better Patient Outcomes

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

An Intro to The Multifaceted Advantages of CDK4/6 Inhibitors in HR+/HER2- Advanced Breast Cancer Clinical Studies.

2.

Iron Deficiency Anemia: Ferric Maltol As a New Treatment Option

3.

Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part II

4.

A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part III

5.

Navigating the Complexities of Ph Negative ALL - Part XIV

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot